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G-quadruplexes are non-canonical secondary structures formed within nucleic acids
that are involved in modulating cellular processes such as replication, gene regulation,
recombination and epigenetics. Within genes, there is mounting evidence of G-quadruplex
involvement in transcriptional and post transcriptional regulation. We report the presence
of potential G-quadruplex motifs within relevant sites of some important pharmacogenes
and discuss the possible implications of this on the function and expression of these
genes. Appreciating the location and potential functions of these motifs may be of value
when considering the impacts of some pharmacogenetic variants. G-quadruplexes are
also the focus of drug development efforts in oncology and we highlight the broader
pharmacological implications of treatment strategies that may target G-quadruplexes.
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INTRODUCTION
The desire to implement pharmacogenetic testing as a means to
improve drug safety and treatment efficacy has led to intense
scrutiny of the functional and clinical relevance of variation
in pertinent genes (Sim et al., 2013). Over 300 human genes
are recognized to be involved in the absorption, distribution,
metabolism, and excretion of drugs, as well as encoding pro-
tein targets for therapeutics (Sangkuhl et al., 2008; Madian et al.,
2012). Extensive cataloging of variants within these genes has
been carried out (Nelson et al., 2012), with the 1000 Genome
Project providing a global view of such variants (Durbin et al.,
2010). In addition, genome wide association studies (GWAS)
and high throughput gene expression analyses are implicating
new genes in drug response phenotypes (Daly, 2012; Madian
et al., 2012; Wheeler and Dolan, 2012). Our ability to interpret
the clinical significance of this growing catalog of gene variants
depends on a fuller appreciation of functional genomic features
(Sadee et al., 2011). Here we seek to highlight the importance of
a genomic feature called the G-quadruplex that has been impli-
cated in many critical cellular functions, and which may be of
considerable interest to those working in pharmacogenomics.
G-quadruplexes (G4s) are stable secondary structures found
in G rich nucleic acids wherein guanine bases associate via
Hoogsteen hydrogen bonds to form tetrads (Figure 1A) that stack
in a planar arrangement with a stabilizing monovalent cation
occupying a central position of the cavity (Sen and Gilbert,
1988; Sundquist and Klug, 1989). G4s can form in one strand
(Figure 1B) or from multiple strands where sequences interven-
ing G tracts of two or more guanines exist as loops of various
sizes (Burge et al., 2006). The stability and topology of G4 are
influenced by several factors including length and sequence com-
position, strand stoichiometry, and orientation, nature of the
binding cation and loop size between G tracts with longer tracts
and small sized loops contributing to more stable structures
(Bugaut and Balasubramanian, 2008; Guedin et al., 2010). The
existence and topology of G4s can be studied in vitro by methods
such as circular dichroism, nuclear magnetic resonance, and X-
ray crystallography whereas fluorescence imaging, small molecule
and protein pull downs, ChIP-Seq and ChIP-chip experiments
can be designed to detect G4s in cellular DNA (Di Antonio et al.,
2012b).
The human genome contains more than 375,000 predicted
G4 forming sequences (Huppert and Balasubramanian, 2005)
with clusters of them occurring in biologically important regions
such as telomeres, promoters, 5′-untranslated regions (UTRs),
3′UTRs, replication origins, exons and introns. G4s are implicated
in maintenance of chromosomal ends, transcription, translation,
DNA replication, alternative splicing, recombination, and epige-
netic stability (Maizels and Gray, 2013). It is not yet clear how
often putative G4motifs actually give rise to G4 structures in vivo,
although this process is expected to be tightly regulated within
different cell types. Evidence for G4 formation in vivo has come
from the identification of G4 interacting cellular proteins and the
ability of small molecules that bind G4 to affect transcription,
translation and replication (Rodriguez, 2012; Biffi et al., 2013;
Valton et al., 2014). Furthermore, the location and composition
of G4s are conserved in human populations, implying that they
play an important role in cellular processes (Eddy and Maizels,
2008).
G4 formation in the promoters of proto-oncogenes has been
linked with repression of transcription; most likely due to poly-
merase pausing at the site of G4 formation. Addition of small
molecule ligands was found to stabilize G4s in the promoters of
the proto-oncogene RET (Shin et al., 2014) and the gene encod-
ing tumor angiogenesis factorVEGF (Salvati et al., 2014) resulting
in altered protein expression. Likewise, RNA G4s in the 5′UTR
of the matrix metalloproteinase (MT3-MMP), estrogen receptor
(ESR1), apoptotic regulator (BCL2), telomere shelterin protein
(TRF2) and several other proteins have been reported to nega-
tively modulate translation in gene-reporter expression studies
(Morris and Basu, 2009; Bugaut and Balasubramanian, 2012).
RNA G4s have also been shown to play a role in alternative
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FIGURE 1 | Structure of G4 and location of predicted G4s within the
CYP2D6 gene. (A) Guanine tetrad formed by the association of four guanine
bases viaHoogsten hydrogen bonds in a coplanar arrangement and stabilized by
a potassium ion. (B) Schematic representation of a G-quadruplex formed by the
stacking of the three guanine tetrads from a single strand of DNA. (C) Location
of predictedG4s in theCYP2D6 gene. Orange arrowheads indicate location and
orientation of predicted G4s; exons are depicted by black blocks. Also indicated
are the locations of SNPs and CYP2D6∗ alleles found within predicted G4s.
splicing and expression patterns of genes Bcl-xL (Hai et al., 2008)
and FMR1(Didiot et al., 2008) while modulation of G4 formation
in the third intron of the tumor supressor gene TP53 was recently
shown to result in varied expression of the p53 transcript (Marcel
et al., 2011).
Owing to the abundance of predicted G4s in the telom-
eric regions of the genome and in promoters of many onco-
genes, including MYC, G4 represent an appealing and novel
target for small-molecule chemotherapeutic development (Verma
et al., 2009; Neidle, 2010). Inhibition of MYC transcription
was achieved by exposing HeLa S3 cells to the small molecule
TMPyP4, which binds to its promoter G4, providing proof of
principle for the targeting of regulatory G4 structures of onco-
genes as a novel therapeutic strategy (Siddiqui-Jain et al., 2002).
Likewise, ongoing research is directed toward promoter G4 medi-
ated transcriptional repression of proto-oncogenes such as the
receptor tyrosine kinase KIT, the small GTPase KRAS, and more
recently of an RNA G4 in the 5′ UTR region of the small GTPase
gene NRAS (Heinrich et al., 2003; Bugaut et al., 2010).
Given the apparent significance of G4s, we have analyzed the
occurrence of potential G-quadruplex forming sequence within
“Very Important Pharmacogenes” (VIP) (Whirl-Carrillo et al.,
2012) using web based G4 prediction algorithms Quadparser
(Wong et al., 2010) and QGRSH (Kikin et al., 2006). The
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VIP is a manually curated list of genes with well described
pharmacogenetic relationships which includes genes that encode
drug targets, metabolic enzymes as well as drug transporters. It is
by no means an exclusive listing of all known pharmacogenes, but
it includes many of the best understood and widely studied phar-
macogenes. Our analysis indicates that predicted G4 are found
in the promoters, 5′UTRs, 3′UTRs, exons, and introns of phar-
macogenes. The position and location of predicted G4 within
the VIP suggests the potential for G4 structures to impact on
pharmacogene expression (Supplementary Table 1).
G4s AND THE REGULATION OF PHARMACOGENES
PROMOTER G4s FUNCTION AS TRANSCRIPTIONAL REGULATORY
ELEMENTS
Studies focused on interaction of promoter G4s within the cell
have revealed a role in transcriptional regulation. The proto-
oncogene MYC which is overexpressed in more than 80% of solid
tumors contains a G4 forming region in the nuclease hypersen-
sitive element of its promoter (Siddiqui-Jain et al., 2002). The
nuclear protein nucleolin promotes G4 formation leading to tran-
scriptional repression (Gonzalez et al., 2009). Conversely, tran-
scriptional activation of this gene is induced by the G4-unwinding
activity of the nucleoside diphosphate kinase NM23H2 protein
(Postel et al., 1993) and poly ADP-ribose polymerase (Fekete
et al., 2012). Palumbo et al. (2008) found that multiple GGA
repeats within the C-MYB promoter form a G4 that acts as a
transcriptional repressor by interacting with Myc-associated Zn
finger proteins. Likewise, transcriptional repression of the human
PDGFB gene was observed by ligand-mediated stabilization of its
promoter G4 (Qin et al., 2010). In addition, it appears that the
transcriptional regulatory protein SP1 can bind to G4 structures
with high affinity, implying a role for transcription factor binding
sites to formG4 as a key determinant for regulation of some genes
(Raiber et al., 2012).
More than 40% of human gene promoters contain at least one
predicted G4 (Huppert and Balasubramanian, 2007); in line with
this our analysis of the VIP list (Whirl-Carrillo et al., 2012) indi-
cates the occurrence of at least one promoter predicted G4 in
38% of these genes (Supplementary Table 1). Among these are
genes encoding important metabolic enzymes (CYP2D6, CYP2J2,
G6PD,TPMT), receptor proteins (ADRB1,ADRB2,DRD2,VDR),
folate transporter (SLC19A1) and proteins involved in potassium
voltage-gated and sodium channels (KCNH2, SCN5A). Presence
of predicted G4 in the promoters of these pharmacogenes is
suggestive of transcriptional regulation at the promoter G4 site.
Mutations or polymorphisms affecting these predicted G4 could
alter stability of secondary structures impacting gene expression
and activity, and this may be important when considering the
regulatory potential of genetic variants. This type of an effect
was demonstrated by the recent observation at rs2255888 of the
lipoxygenase gene ALOX15 promoter implicated in pathogene-
sis of atherosclerosis. Using biophysical and in vitro studies the
G but not the A allele at this position was found to be involved
in the DNA secondary structure formation (although this did
not appear to be a G4), affecting binding of the cytoskeleton
protein vimentin and resulting in altered transcriptional regula-
tion (Samanta et al., 2012).
ROLE OF RNA G4s IN POST TRANSCRIPTIONAL REGULATION
Evidence has emerged for the role of G4s not only in tran-
scription but also in post transcriptional regulation, as G4s can
readily form in RNA molecules (Biffi et al., 2014). RNA G4s
occur within the 5′UTR, exons, introns and 3′UTRs where they
regulate translation, alternative splicing and expression patterns
(Marcel et al., 2011; Bugaut and Balasubramanian, 2012; Endoh
et al., 2013; Murat et al., 2014). G4s formed in the 5′UTR were
found to play a role in translational down-regulation of genes
with cap-dependent translation (Morris and Basu, 2009; Bugaut
and Balasubramanian, 2012) whereas they have been shown to
mediate internal ribosome entry site translation initiation in
cap-independent translation (Bonnal et al., 2003; Morris et al.,
2010).
Our analysis revealed G4 motifs in the 5′UTRs of the phar-
macogenes G6PD, GSTP1, KCNH2, and PTGIS (Supplementary
Table 1), suggesting these motifs have the potential to affect
translational efficiencies and modulate protein expression lev-
els. Detailed in silico, in vitro and cellular analysis of
SNPs among 5′UTR predicted RNA G4s provide further
evidence for G4 involvement in translation (Beaudoin and
Perreault, 2010). Beaudoin and Perreault (2010) demonstrated
that a G to C substitution within the 5′UTR RNA G4
of AASDHPPT (L-aminoadipate-semialdehyde dehydrogenase-
phosphopantetheinyl transferase) restricted G4 formation by
favoring stem loop structures, which led to increased translation
efficiency of a reporter gene. This example also illustrates the
potential significance of SNPs within G4 of 5′UTRs in causing
differential gene expression among individuals.
Our investigation of G4 motifs in the VIP gene set also reveals
that 20% of the genes queried contain a predicted G4 in their
3′UTR. This includes ACE, ADRB1, CYP2A6, G6PD, MTHFR,
SLC19A1, and VDR (Supplementary Table 1). The presence of
predicted G4s in the 3′UTR implies a role for RNA G4s in other
stages of RNAmetabolism. A 3′UTR in the PIM1 proto-oncogene
was reported to reduce translation efficiency (Arora and Suess,
2011). Recent findings indicate that 3′UTR G4s can also reg-
ulate gene expression by increasing the efficiencies of alternate
polyadenylation sites leading to expression of shorter transcripts,
and eluding of the miRNA regulatory network (Beaudoin and
Perreault, 2013).
POTENTIAL G4s IN THE CYP2D6 GENE
The highly polymorphic CYP2D6 gene is of particular phar-
macogenetic interest owing to its implications for metabolism
of a variety of drugs (Becker and Leeder, 2010). We detected a
total of eight predicted G4s in this gene (Supplementary Table 1;
Figure 1C) with one present 437 bp upstream from the transcrip-
tional start site in the promoter region which could potentially
influence transcriptional regulation. We also observed predicted
G4 within introns 2, 3, 5, and 6 in an orientation such that
they would occur in nuclear pre-mRNA transcripts (Figure 1C),
with possible relevance to RNA processing. Notably, some of
the CYP2D6∗ alleles involved in poor and rapid metabolizer
phenotypes are situated within predicted G4s. Among these
are CYP2D6∗1D (rs28371718), CYP2D6∗4K (rs67780109),
CYP2D6∗4C (rs3892097), CYP2D6∗30 (rs72549356) and
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CYP2D6∗41 (rs28371725). Furthermore, dbSNPs rs76326664
(A/G), rs77952980 (A/G), rs4992866 (C/T) are located within
predicted G4 in CYP2D6 introns where they may affect G4
formation and stability. In addition to SNPs, mutations such as
insertions, deletions, and gene rearrangements all have the ability
to exert effects on G4 stability and hence perturb their role in
transcriptional or translational regulation.
G4s AS DRUG TARGETS
G4 INTERACTING LIGANDS IN CANCER THERAPY
The large amount of research into G4 ligand induced gene
regulation over the last decade has led to several G4 targeting
compounds that are currently under investigation as potential
chemotherapeutic drugs. G4 targeting anticancer drugs evaluated
for some well-studied proto-oncogenes alongside their advantage
and disadvantages are listed in Table 1. The first line of ligands
such as the tri-substituted acridines targeted the terminal quartet
present at the top and bottom of the G4 structure (Mergny et al.,
2002). Platinum-derived complexes have been shown to prefer-
entially target the MYC G4 structure over duplex DNA (Wang
et al., 2013). The fluoroquinone derivative quarfloxin was the first
G4-interacting compound to reach Phase II clinical trials, with
potential for the treatment of neuroendocrine tumors (Drygin
et al., 2009). Its ability to strongly interact with parallel G4
structures has been studied in detail within the cellular context.
Although treatment with quarfloxin revealed the absence of organ
or genotoxicity, it led to the disruption of interaction between
nucleolin and ribosomal RNA G4 with consequent inhibition of
Pol I driven transcription and redistribution of nucleolin within
the cell, limiting its bioavailability (Balasubramanian et al., 2011).
As chemotherapeutic drugs that target regulatory G4 enter
and move through clinical trials it may be prudent to consider
whether binding of drugs to non-target G4s could impact on
expression of genes that are important in metabolism of other
chemotherapeutic drugs and xenobiotics. We have identified
predicted G4 in a number of pharmacogenes relevant to the
treatment of cancer (Supplementary Table 1) which could con-
ceivably be impacted by such off target effects of G4 drugs.
For example, if a G4 targeting drug also targets the predicted
G4 in the promoter of CYP2D6 gene that is involved in
transcriptional repression, it may result in reduced efficacy
of other drugs that are metabolized by CYP2D6, like tamox-
ifen (Province et al., 2014). Similar situations could arise if
the drug targeted G4s within the TPMT or UGT1A1 gene
whose products are involved in metabolism of thiopurine drugs
(Weinshilboum, 2001), and irinotecan (Wang et al., 2011)
respectively.
MORE WIDESPREAD OPPORTUNITIES FOR G4 BASED THERAPEUTICS?
Although much effort has been directed toward understanding
G4s in proto-oncogenes and more recently cardiovascular genes
(Zhou et al., 2013), there has been little consideration of the
potential significance of G4s in many of the genes that impact
on responses to treatment of these and other diseases. Among
these are the G-protein coupled receptors, ADRB1 and ADRB2
involved in mediating heart rate, contractibility, bronchodilator
response and cardiomyopathy (Sandilands and O’shaughnessy,
2005; Lymperopoulos and Bathgate, 2012). It is worth considering
whether G4 formation in these and other important pharma-
cogenes could represent valid targets for modification of drug
metabolism using targeted therapeutics.
We detected putative G4 in the promoter and 5′UTR of the
TPMT gene (Supplementary Table 1), and it may be of value to
investigate the formation of G4s and the role they may play in the
regulation of this gene product as it is involved in the treatment of
autoimmune diseases, inflammatory bowel disease, lupus, trans-
plantation, and acute lymphoblastic leukemia (Lennard, 2002).
We also described variant trinucleotide repeats within the pro-
moter of TPMT from two patients with ultra-high activity of
this enzyme, which showed increased transcriptional activity in
reporter gene assays (Roberts et al., 2008). These GCC repeat
arrays may be capable of forming G4 structures, and different
forms of these could conceivably contribute to different levels of
transcriptional activity.
In addition to CYP2D6, discussed above, other predicted
G4 containing pharmacogenes include UGT1A1, involved in
bilirubin metabolism and degradation and removal of xenobi-
otic waste (Tukey and Strassburg, 2000); CYP2A6, best known
Table 1 | List of G4 binding anticancer drugs tested.
G-quadruplex interacting drug Advantage Disadvantage References
Trisubstituted acridines Targets large aromatic surface at top and
bottom of G4, effective telomerase
inhibitor
Non-specific interactions Mergny et al., 2002
Quindoline and Berberine Antiproliferative, Myc downregulation in
cancer cell lines
Binds duplex DNA,
non-specific interactions
Ou et al., 2007
TyMPYP4 Transcriptional repression of MYC Non-specific interactions Siddiqui-Jain et al., 2002
Trisubstituted isoalloxazines Stabilizes KIT promoter G4, transcriptional
repression
Non-specific interactions Bejugam et al., 2007
Telomestatin Antitelomerase and anti-Myc activity Non-specific interactions Kim et al., 2002
Naphthalene diimide Dose dependant cell arrest of mutated KIT
cell lines
Non-specific interactions Gunaratnam et al., 2009
Platinum derived complexes Targets G4 of c-MYC over duplex Non-specific interactions
if any are yet to be
determined
Wang et al., 2013
Quarfloxin Interacts with parallel G4 Limited bioavailability Drygin et al., 2009
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for its role in conversion of nicotine to cotinine (Benowitz et al.,
2006); and MTHFR, important in folate and methionine biosyn-
thesis (Marini et al., 2008) as well as de novo purine biosynthesis
(Jongbloet et al., 2008) and DNA methylation. Determining the
formation of G4 structures at these sites and establishing whether
this is of pharmacogenetic significance is important as there may
be merit in exploring novel strategies for targeting G4 mediated
regulation in these and other genes.
FUTURE OF G4 DRUG TARGETING
The quest to identify and devise G4 binding ligands has gar-
nered much attention in the last few years. Development of small
molecules with high specificity and affinity for a particular G4
could also be achieved by using structure-based design meth-
ods and screening against virtual compound libraries (Ma et al.,
2011). Investigation of the alkyl derivative of TMPyP4 (TMpyP4-
C14), led to the observation that TMpyP4-C14 could efficiently
enter cells and preferentially localize into the cytoplasm with
binding to G4 structures in the 5′UTR of KRAS mRNA, resulting
in 90% down regulation of KRAS protein expression in pancre-
atic cancer cells (Xodo et al., 2008). Small molecules like the
pyridine-2,6-bis-quinolinodicarboxamide derivative and its vari-
ant have been shown to specifically decrease translation efficiency
by stabilizing a G4 in the 5′UTR of the NRAS proto-oncogene
(Bugaut and Balasubramanian, 2012). In situ click chemistry is
another promising approach aimed at enhancing the interaction
specificity of a small molecule G4 ligand to its corresponding
nucleic acid structure (Di Antonio et al., 2012a). Virtual screen-
ing approaches on the other hand have identified novel G4 ligands
(Alcaro et al., 2013; Gonzalez et al., 2013). Another approach to
molecules with selective affinity for specific G4 is to generate spe-
cific antibodies (Fernando et al., 2009). Huppert (2007) presented
the idea of adding functional specificity to the G4 binding ligand
by tagging it with sequence specific complementarity to its neigh-
boring DNA. The biological activity of these compounds depends
on the structural interaction of G4 small molecule ligand com-
plexes to disrupt normal regulatory processes that may involve
the targeted G4 structure.
G4 aptamers that bind to and block clinically relevant proteins
are the converse situation, and the prototypical molecule of this
class is the thrombin binding G4 aptamer which inhibits throm-
bin catalyzed clot formation (Nagatoishi et al., 2011). Similarly,
HIV DNA integration into the genome was shown to be inhibited
by binding of G4 aptamers to the HIV integrase protein (Do et al.,
2011). Finally, G4 decoys could be explored in treating patients
that harbor G4 alleviating SNPs in clinically relevant genes. This
strategy was shown to successfully mediate apoptosis in HeLa
and T24 urinary bladder cancer cells expressing the hyper acti-
vated HRAS protein. G4 decoys designed to mimic the promoter
G4s of the HRAS proto-oncogene functioned as transcriptional
repressors (Membrino et al., 2011). Introduction of G4 decoys
also resulted in effective inhibition of KRAS and tumor growth
arrest in pancreatic cancer cells (Cogoi et al., 2013).
CONCLUSION
Among the many DNA and RNA structures that have been
described, G4s have gained increasing prominence because of
their implication in so many fundamental cellular, evolution-
ary and genomic processes (Wu and Brosh, 2010; Maizels and
Gray, 2013). Although there is an increased understanding of
the role played by G4s in a number of cellular processes the
structural intricacies of G4 motifs associated with specific func-
tion remain to be explored. Small molecule based G4 bind-
ing ligands have proved successful in regulating transcription
and expression of proto-oncogenes, providing a novel approach
to the treatment of cancerous cells (Siddiqui-Jain et al., 2002;
Gunaratnam et al., 2009). Our survey revealed several impor-
tant pharmacogenes that harbor one or more predicted G4 in
relevant sites that may contribute to regulation and expression.
Investigating the role of these predicted G4s may also provide
evidence for alternative targets through which specific regula-
tion of pharmacogenes could be achieved in situations where
this may confer clinical benefit. While G4s located in regula-
tory regions of pharmacogenes may provide opportunities for
pharmacokinetic modulation by small molecules that target G4,
they also represent a risk for off-target regulatory effects of
chemotherapeutics designed to target regulatory G4 in onco-
genes. For example, tamoxifen and codeine are both prodrugs that
are activated by CYP2D6. If a small molecule designed to target
an oncogene G4 also acted on the G4 sites in CYP2D6, reduc-
ing expression of this metabolic enzyme, unexpected effects on
the efficacy of tamoxifen or codeine could occur. Alternatively,
if the chemotherapeutic drug itself was a substrate of CYP2D6,
then concurrent modulation of CYP2D6 via off-target G4 bind-
ing could markedly affect the pharmacokinetic behavior of the
drug.
Finally, G4 structures are also vulnerable to modulation by
mutation or polymorphism, so our analysis has the potential to
assign regulatory significance to newly discovered pharmacoge-
netic variants that may affect function by impacting on such
structural features. Because pharmacogenes, like oncogenes and
other classes of genes, have the potential to be regulated by for-
mation of G4s within either genomic DNA or RNA transcripts, it
is our hope that the knowledge of G4 structures and considera-
tion of their potential to be modified may provide useful insights
in the field of pharmacogenomics.
ACKNOWLEDGMENTS
Supported by the Carney Centre for Pharmacogenomics, and the
Marsden Fund Council (New Zealand) administered by the Royal
Society of New Zealand.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: http://www.frontiersin.org/journal/10.3389/fphar.2014.
00160/abstract
REFERENCES
Alcaro, S., Musetti, C., Distinto, S., Casatti, M., Zagotto, G., Artese, A., et al. (2013).
Identification and characterization of new DNA G-quadruplex binders selected
by a combination of ligand and structure based virtual screening approaches. J.
Med. Chem. 56, 843–855. doi: 10.1021/jm3013486
Arora, A., and Suess, B. (2011). An RNA G-quadruplex in the 3′ UTR of
the proto-oncogene PIM1 represses translation. RNA Biol. 8, 802–805. doi:
10.4161/rna.8.5.16038
www.frontiersin.org July 2014 | Volume 5 | Article 160 | 5
Cree and Kennedy G4s in pharmacogenes
Balasubramanian, S., Hurley, L. H., and Neidle, S. (2011). Targeting G-
quadruplexes in gene promoters: a novel anticancer strategy? Nat. Rev. Drug
discov. 10, 261–275. doi: 10.1038/nrd3428
Beaudoin, J. D., and Perreault, J. P. (2010). 5′-UTR G-quadruplex structures
acting as translational repressors. Nucleic Acids Res. 38, 7022–7036. doi:
10.1093/nar/gkq557
Beaudoin, J. D., and Perreault, J. P. (2013). Exploring mRNA 3′-UTR G-
quadruplexes: evidence of roles in both alternative polyadenylation and
mRNA shortening. Nucleic Acids Res. 41, 5898–5911. doi: 10.1093/nar/
gkt265
Becker, M. L., and Leeder, J. S. (2010). Identifying genomic and developmental
causes of adverse drug reactions in children. Pharmacogenomics 11, 1591–1602.
doi: 10.2217/pgs.10.146
Bejugam, M., Sewitz, S., Shirude, P. S., Rodriguez, R., Shahid, R., and
Balasubramanian, S. (2007). Trisubstituted isoalloxazines as a new class of
G-quadruplex binding ligands: small molecule regulation of c-kit onco-
gene expression. J. Am. Chem. Soc. 129, 12926–12927. doi: 10.1021/
ja075881p
Benowitz, N. L., Swan, G. E., Jacob, P. 3rd., Lessov-Schlaggar, C. N., and Tyndale,
R. F. (2006). CYP2A6 genotype and the metabolism and disposition kinet-
ics of nicotine. Clin. Pharmacol. Ther. 80, 457–467. doi: 10.1016/j.clpt.2006.
08.011
Biffi, G., Di Antonio, M., Tannahill, D., and Balasubramanian, S. (2014).
Visualization and selective chemical targeting of RNA G-quadruplex structures
in the cytoplasm of human cells.Nat. Chem. 6, 75–80. doi: 10.1038/nchem.1805
Biffi, G., Tannahill, D., McCafferty, J., and Balasubramanian, S. (2013).
Quantitative visualization of DNAG-quadruplex structures in human cells.Nat.
Chem. 5, 182–186. doi: 10.1038/nchem.1548
Bonnal, S., Schaeffer, C., Creancier, L., Clamens, S., Moine, H., Prats, A. C.,
et al. (2003). A single internal ribosome entry site containing a G quartet
RNA structure drives fibroblast growth factor 2 gene expression at four alter-
native translation initiation codons. J. Biol. Chem. 278, 39330–39336. doi:
10.1074/jbc.M305580200
Bugaut, A., and Balasubramanian, S. (2008). A sequence-independent study
of the influence of short loop lengths on the stability and topology of
intramolecular DNA G-quadruplexes. Biochemistry 47, 689–697. doi: 10.1021/
bi701873c
Bugaut, A., and Balasubramanian, S. (2012). 5′-UTR RNA G-quadruplexes:
translation regulation and targeting. Nucleic Acids Res. 40, 4727–4741. doi:
10.1093/nar/gks068
Bugaut, A., Rodriguez, R., Kumari, S., Hsu, S. T., and Balasubramanian, S. (2010).
Small molecule-mediated inhibition of translation by targeting a native RNA
G-quadruplex. Org. Biomol. Chem. 8, 2771–2776. doi: 10.1039/c002418j
Burge, S., Parkinson, G. N., Hazel, P., Todd, A. K., and Neidle, S. (2006).
Quadruplex DNA: sequence, topology and structure. Nucleic Acids Res. 34,
5402–5415. doi: 10.1093/nar/gkl655
Cogoi, S., Zorzet, S., Rapozzi, V., Geci, I., Pedersen, E. B., and Xodo, L. E.
(2013). MAZ-binding G4-decoy with locked nucleic acid and twisted interca-
lating nucleic acid modifications suppresses KRAS in pancreatic cancer cells
and delays tumor growth in mice. Nucleic Acids Res. 41, 4049–4064. doi:
10.1093/nar/gkt127
Daly, A. K. (2012). Genetic polymorphisms affecting drug metabolism: recent
advances and clinical aspects. Adv. Pharmacol. 63, 137–167. doi: 10.1016/B978-
0-12-398339-8.00004-5
Di Antonio, M., Biffi, G., Mariani, A., Raiber, E. A., Rodriguez, R., and
Balasubramanian, S. (2012a). Selective RNA vs. DNA G-quadruplex targeting
by in situ click chemistry. Angew. Chem. Int. Ed. Engl. 51, 11073–11078. doi:
10.1002/anie.201206281
Di Antonio, M., Rodriguez, R., and Balasubramanian, S. (2012b). Experimental
approaches to identify cellular G-quadruplex structures and functions. Methods
57, 84–92. doi: 10.1016/j.ymeth.2012.01.008
Didiot, M. C., Tian, Z., Schaeffer, C., Subramanian, M., Mandel, J. L., and Moine,
H. (2008). The G-quartet containing FMRP binding site in FMR1 mRNA
is a potent exonic splicing enhancer. Nucleic Acids Res. 36, 4902–4912. doi:
10.1093/nar/gkn472
Do, N. Q., Lim, K. W., Teo, M. H., Heddi, B., and Phan, A. T. (2011). Stacking
of G-quadruplexes: NMR structure of a G-rich oligonucleotide with poten-
tial anti-HIV and anticancer activity. Nucleic Acids Res.39, 9448–9457. doi:
10.1093/nar/gkr539
Drygin, D., Siddiqui-Jain, A., O’brien, S., Schwaebe, M., Lin, A., Bliesath, J., et al.
(2009). Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.
Cancer Res. 69, 7653–7661. doi: 10.1158/0008-5472.CAN-09-1304
Durbin, R. M., Abecasis, G. R., Altshuler, D., Auton, A., Brooks, L. D., Gibbs, R.
A., et al. (2010). A map of human genome variation from population-scale
sequencing. Nature 467, 1061–1073. doi: 10.1038/nature09534
Eddy, J., and Maizels, N. (2008). Conserved elements with potential to form poly-
morphic G-quadruplex structures in the first intron of human genes. Nucleic
Acids Res. 36, 1321–1333. doi: 10.1093/nar/gkm1138
Endoh, T., Kawasaki, Y., and Sugimoto, N. (2013). Suppression of gene expres-
sion by G-quadruplexes in open reading frames depends on G-quadruplex
stability. Angew. Chem. Int. Ed. Engl. 52, 5522–5526. doi: 10.1002/anie.
201300058
Fekete, A., Kenesi, E., Hunyadi-Gulyas, E., Durgo, H., Berko, B., Dunai, Z. A., et al.
(2012). The guanine-quadruplex structure in the human c-myc gene’s promoter
is converted into B-DNA form by the human poly(ADP-ribose)polymerase-1.
PLoS ONE 7:e42690. doi: 10.1371/journal.pone.0042690
Fernando, H., Sewitz, S., Darot, J., Tavare, S., Huppert, J. L., and Balasubramanian,
S. (2009). Genome-wide analysis of a G-quadruplex-specific single-chain anti-
body that regulates gene expression. Nucleic Acids Res. 37, 6716–6722. doi:
10.1093/nar/gkp740
Gonzalez, D. C., Machado, G. P., Guedin, A., Mergny, J. L., and And Cabrera-
Perez, M. A. (2013). FDA-approved drugs selected using virtual screening
bind specifically to G-Quadruplex DNA. Curr. Pharm. Des. 19, 2164. doi:
10.2174/1381612811319120004
Gonzalez, V., Guo, K., Hurley, L., and Sun, D. (2009). Identification and charac-
terization of nucleolin as a c-myc G-quadruplex-binding protein. J. Biol. Chem.
284, 23622–23635. doi: 10.1074/jbc.M109.018028
Guedin, A., Gros, J., Alberti, P., and Mergny, J. L. (2010). How long is too long?
Effects of loop size on G-quadruplex stability. Nucleic Acids Res. 38, 7858–7868.
doi: 10.1093/nar/gkq639
Gunaratnam, M., Swank, S., Haider, S. M., Galesa, K., Reszka, A. P., Beltran,
M., et al. (2009). Targeting human gastrointestinal stromal tumor cells with
a quadruplex-binding small molecule. J. Med. Chem. 52, 3774–3783. doi:
10.1021/jm900424a
Hai, Y., Cao, W., Liu, G., Hong, S. P., Elela, S. A., Klinck, R., et al. (2008). A G-tract
element in apoptotic agents-induced alternative splicing. Nucleic Acids Res. 36,
3320–3331. doi: 10.1093/nar/gkn207
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., Von Mehren, M.,
Joensuu, H., et al. (2003). Kinase mutations and imatinib response in patients
with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342–4349.
doi: 10.1200/JCO.2003.04.190
Huppert, J. L. (2007). Four-stranded DNA: cancer, gene regulation and drug
development. Philos. Trans. A Math. Phys.Eng. Sci. 365, 2969–2984. doi:
10.1098/rsta.2007.0011
Huppert, J. L., and Balasubramanian, S. (2005). Prevalence of quadruplexes
in the human genome. Nucleic Acids Res. 33, 2908–2916. doi: 10.1093/nar/
gki609
Huppert, J. L., and Balasubramanian, S. (2007). G-quadruplexes in promot-
ers throughout the human genome. Nucleic Acids Res. 35, 406–413. doi:
10.1093/nar/gkl1057
Jongbloet, P. H., Verbeek, A. L., Den Heijer, M., and Roeleveld, N. (2008).
Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms resulting
in suboptimal oocyte maturation: a discussion of folate status, neural tube
defects, schizophrenia, and vasculopathy. J. Exp. Clin. Assis. Reprod. 5:5. doi:
10.1186/1743-1050-5-5
Kikin, O., D’antonio, L., and Bagga, P. S. (2006). QGRSMapper: a web-based server
for predicting G-quadruplexes in nucleotide sequences. Nucleic Acids Res. 34,
W676–W682. doi: 10.1093/nar/gkl253
Kim, M. Y., Vankayalapati, H., Shin-Ya, K., Wierzba, K., and Hurley, L. H. (2002).
Telomestatin, a potent telomerase inhibitor that interacts quite specifically with
the human telomeric intramolecular g-quadruplex. J. Am. Chem. Soc. 124,
2098–2099. doi: 10.1021/ja017308q
Lennard, L. (2002). TPMT in the treatment of Crohn’s disease with azathioprine.
Gut 51, 143–146. doi: 10.1136/gut.51.2.143
Lymperopoulos, A., and Bathgate, A. (2012). Pharmacogenomics of the
heptahelical receptor regulators G-protein-coupled receptor kinases and
arrestins: the known and the unknown. Pharmacogenomics 13, 323–341. doi:
10.2217/pgs.11.178
Frontiers in Pharmacology | Pharmacogenetics and Pharmacogenomics July 2014 | Volume 5 | Article 160 | 6
Cree and Kennedy G4s in pharmacogenes
Ma, D. L., Chan, D. S., Lee, P., Kwan, M. H., and Leung, C. H. (2011). Molecular
modeling of drug-DNA interactions: virtual screening to structure-based
design. Biochimie 93, 1252–1266. doi: 10.1016/j.biochi.2011.04.002
Madian, A. G., Wheeler, H. E., Jones, R. B., and Dolan, M. E. (2012). Relating
human genetic variation to variation in drug responses. Trends Genet. 28,
487–495. doi: 10.1016/j.tig.2012.06.008
Maizels, N., and Gray, L. T. (2013). The G4 Genome. PLoS Genet. 9:e1003468. doi:
10.1371/journal.pgen.1003468
Marcel, V., Tran, P. L., Sagne, C., Martel-Planche, G., Vaslin, L., Teulade-Fichou, M.
P., et al. (2011). G-quadruplex structures in TP53 intron 3: role in alternative
splicing and in production of p53 mRNA isoforms. Carcinogenesis 32, 271–278.
doi: 10.1093/carcin/bgq253
Marini, N. J., Gin, J., Ziegle, J., Keho, K. H., Ginzinger, D., Gilbert, D. A.,
et al. (2008). The prevalence of folate-remedial MTHFR enzyme variants in
humans. Proc. Natl. Acad. Sci. U.S.A. 105, 8055–8060. doi: 10.1073/pnas.0802
813105
Membrino, A., Cogoi, S., Pedersen, E. B., and Xodo, L. E. (2011). G4-DNA
formation in the HRAS promoter and rational design of decoy oligonu-
cleotides for cancer therapy. PLoS ONE 6:e24421. doi: 10.1371/journal.pone.
0024421
Mergny, J. L., Riou, J. F., Mailliet, P., Teulade-Fichou, M. P., and Gilson, E. (2002).
Natural and pharmacological regulation of telomerase. Nucleic Acids Res. 30,
839–865. doi: 10.1093/nar/30.4.839
Morris, M. J., and Basu, S. (2009). An unusually stable G-quadruplex
within the 5-UTR of the MT3 matrix metalloproteinase mRNA represses
translation in eukaryotic cells. Biochemistry 48, 5313–5319. doi: 10.1021/
bi900498z
Morris, M. J., Negishi, Y., Pazsint, C., Schonhoft, J. D., and Basu, S. (2010).
An RNA G-quadruplex is essential for cap-independent translation initiation
in human VEGF IRES. J. Am. Chem. Soc. 132, 17831–17839. doi: 10.1021/
ja106287x
Murat, P., Zhong, J., Lekieffre, L., Cowieson, N. P., Clancy, J. L., Preiss, T.,
et al. (2014). G-quadruplexes regulate Epstein-Barr virus-encoded nuclear anti-
gen 1 mRNA translation. Nat. Chem. Biol. 10, 358–364. doi: 10.1038/nchem-
bio.1479
Nagatoishi, S., Isono, N., Tsumoto, K., and Sugimoto, N. (2011). Loop residues of
thrombin-binding DNA aptamer impact G-quadruplex stability and thrombin
binding. Biochimie 93, 1231–1238. doi: 10.1016/j.biochi.2011.03.013
Neidle, S. (2010). Human telomeric G-quadruplex: the current status of telomeric
G-quadruplexes as therapeutic targets in human cancer. FEBS J. 277, 1118–1125.
doi: 10.1111/j.1742-4658.2009.07463.x
Nelson, M. R., Wegmann, D., Ehm, M. G., Kessner, D., St Jean, P., Verzilli, C.,
et al. (2012). An abundance of rare functional variants in 202 drug target
genes sequenced in 14,002 people. Science 337, 100–104. doi: 10.1126/science.
1217876
Ou, T. M., Lu, Y. J., Zhang, C., Huang, Z. S., Wang, X. D., Tan, J. H., et al.
(2007). Stabilization of G-quadruplex DNA and down-regulation of oncogene
c-myc by quindoline derivatives. J. Med. Chem. 50, 1465–1474. doi: 10.1021/
jm0610088
Palumbo, S. L., Memmott, R. M., Uribe, D. J., Krotova-Khan, Y., Hurley, L. H., and
Ebbinghaus, S. W. (2008). A novel G-quadruplex-forming GGA repeat region
in the c-myb promoter is a critical regulator of promoter activity. Nucleic Acids
Res. 36, 1755–1769. doi: 10.1093/nar/gkm1069
Postel, E. H., Berberich, S. J., Flint, S. J., and Ferrone, C. A. (1993). Human c-
myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate
kinase, a candidate suppressor of tumor metastasis. Science 261, 478–480. doi:
10.1126/science.8392752
Province, M. A., Goetz, M. P., Brauch, H., Flockhart, D. A., Hebert, J. M., Whaley,
R., et al. (2014). CYP2D6 genotype and adjuvant tamoxifen: meta-analysis
of heterogeneous study populations. Clin. Pharmacol. Ther. 95, 216–227. doi:
10.1038/clpt.2013.186
Qin, Y., Fortin, J. S., Tye, D., Gleason-Guzman, M., Brooks, T. A., and Hurley,
L. H. (2010). Molecular cloning of the human platelet-derived growth factor
receptor beta (PDGFR-beta) promoter and drug targeting of the G-quadruplex-
forming region to repress PDGFR-beta expression. Biochemistry 49, 4208–4219.
doi: 10.1021/bi100330w
Raiber, E. A., Kranaster, R., Lam, E., Nikan, M., and Balasubramanian, S. (2012).
A non-canonical DNA structure is a binding motif for the transcription factor
SP1 in vitro. Nucleic Acids Res. 40, 1499–1508. doi: 10.1093/nar/gkr882
Roberts, R. L., Gearry, R. B., Bland, M. V., Sies, C. W., George, P. M., Burt, M.,
et al. (2008). Trinucleotide repeat variants in the promoter of the thiopurine
S-methyltransferase gene of patients exhibiting ultra-high enzyme activity.
Pharmacogenet. Genomics 18, 434–438. doi: 10.1097/FPC.0b013e3282f85e47
Rodriguez, R. (2012). Small-molecule induced DNA damage identifies alter-
native DNA structures in human genes. Nat. Chem. Biol. 8, 301–310. doi:
10.1038/nchembio.780
Sadee, W., Wang, D., Papp, A. C., Pinsonneault, J. K., Smith, R. M., Moyer,
R. A., et al. (2011). Pharmacogenomics of the RNA world: structural RNA
polymorphisms in drug therapy. Clin. Pharmacol. Ther. 89, 355–365. doi:
10.1038/clpt.2010.314
Salvati, E., Zizza, P., Rizzo, A., Iachettini, S., Cingolani, C., D’angelo, C., et al.
(2014). Evidence for G-quadruplex in the promoter of vegfr-2 and its tar-
geting to inhibit tumor angiogenesis. Nucleic Acids Res. 42, 2945–2957. doi:
10.1093/nar/gkt1289
Samanta, S., Anderson, K., Moran, S., Hawke, D., Gorenstein, D., and Fornage, M.
(2012). Characterization of a human 12/15-lipoxygenase promoter variant asso-
ciated with atherosclerosis identifies vimentin as a promoter binding protein.
PLoS ONE 7:e42417. doi: 10.1371/journal.pone.0042417
Sandilands, A. J., and O’shaughnessy, K. M. (2005). The functional significance
of genetic variation within the beta-adrenoceptor. Br. J. Clin. Pharmacol. 60,
235–243. doi: 10.1111/j.1365-2125.2005.02438.x
Sangkuhl, K., Berlin, D. S., Altman, R. B., and Klein, T. E. (2008). PharmGKB:
understanding the effects of individual genetic variants. Drug Metab. Rev. 40,
539–551. doi: 10.1080/03602530802413338
Sen, D., and Gilbert, W. (1988). Formation of parallel four stranded complexes by
guanine-rich motifs and its implications for meiosis. Nature 334, 364–366. doi:
10.1038/334364a0
Shin, Y. J., Kumarasamy, V., Camacho, D., and Sun, D. (2014). Involvement of G-
quadruplex structures in regulation of human RET gene expression by small
molecules in human medullary thyroid carcinoma TT cells. Oncogene. doi:
10.1038/onc.2014.65. [Epub ahead of print].
Siddiqui-Jain, A., Grand, C. L., Bearss, D. J., and Hurley, L. H. (2002). Direct
evidence for a G-quadruplex in a promoter region and its targeting with a
small molecule to repress c-MYC transcription. Proc. Natl. Acad. Sci. U.S.A. 99,
11593–11598. doi: 10.1073/pnas.182256799
Sim, S. C., Kacevska, M., and Ingelman-Sundberg, M. (2013). Pharmacogenomics
of drug-metabolizing enzymes: a recent update on clinical implications and
endogenous effects. Pharmacogenomics J. 13, 1–11. doi: 10.1038/tpj.2012.45
Sundquist, W. I., and Klug, A. (1989). Telomeric DNA dimerizes by forma-
tion of guanine tetrads between hairpin loops. Nature 342, 825–829. doi:
10.1038/342825a0
Tukey, R. H., and Strassburg, C. P. (2000). Human UDP-glucuronosyltransferases:
metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40,
581–616. doi: 10.1146/annurev.pharmtox.40.1.581
Valton, A. L., Hassan-Zadeh, V., Lema, I., Boggetto, N., Alberti, P., Saintome, C.,
et al. (2014). G4 motifs affect origin positioning and efficiency in two vertebrate
replicators. EMBO J. 33, 732–746. doi: 10.1002/embj.201387506
Verma, A., Yadav, V. K., Basundra, R., Kumar, A., and Chowdhury, S. (2009).
Evidence of genome-wide G4 DNA-mediated gene expression in human cancer
cells. Nucleic Acids Res. 37, 4194–4204. doi: 10.1093/nar/gkn1076
Wang, J., Lu, K., Xuan, S., Toh, Z., Zhang, D., and Shao, F. (2013). A Pt(II)-Dip com-
plex stabilizes parallel c-myc G-quadruplex. Chem. Commun. 49, 4758–4760.
doi: 10.1039/c3cc40868j
Wang, L., McLeod, H. L., and Weinshilboum, R. M. (2011). Genomics and drug
response. New Engl. J. Med. 364, 1144–1153. doi: 10.1056/NEJMra1010600
Weinshilboum, R. (2001). Thiopurine pharmacogenetics: clinical and molecular
studies of thiopurine methyltransferase. Drug Metab. Dispos 29, 601–605.
Wheeler, H. E., and Dolan, M. E. (2012). Lymphoblastoid cell lines in pharma-
cogenomic discovery and clinical translation. Pharmacogenomics 13, 55–70. doi:
10.2217/pgs.11.121
Whirl-Carrillo,M.,McDonagh, E.M., Hebert, J. M., Gong, L., Sangkuhl, K., Thorn,
C. F., et al. (2012). Pharmacogenomics knowledge for personalized medicine.
Clin. Pharmacol. Ther. 92, 414–417. doi: 10.1038/clpt.2012.96
Wong, H. M., Stegle, O., Rodgers, S., and Huppert, J. L. (2010). A toolbox for pre-
dicting g-quadruplex formation and stability. J. Nucleic Acids 2010:564946. doi:
10.4061/2010/564946
Wu, Y., and Brosh, R. M. Jr. (2010). G-quadruplex nucleic acids and human disease.
FEBS J. 277, 3470–3488. doi: 10.1111/j.1742-4658.2010.07760.x
www.frontiersin.org July 2014 | Volume 5 | Article 160 | 7
Cree and Kennedy G4s in pharmacogenes
Xodo, L., Paramasivam,M., Membrino, A., and Cogoi, S. (2008). Protein hnRNPA1
binds to a critical G-rich element of KRAS and unwinds G-quadruplex struc-
tures: implications in transcription. Nucleic Acids Symp. Ser. 159–160. doi:
10.1093/nass/nrn081
Zhou, W., Suntharalingam, K., Brand, N. J., Barton, P. J., Vilar, R., and Ying,
L. (2013). Possible regulatory roles of promoter g-quadruplexes in cardiac
function-related genes - human TnIc as a model. PLoS ONE 8:e53137. doi:
10.1371/journal.pone.0053137
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 11 April 2014; accepted: 19 June 2014; published online: 08 July 2014.
Citation: Cree SL and Kennedy MA (2014) Relevance of G-quadruplex structures to
pharmacogenetics. Front. Pharmacol. 5:160. doi: 10.3389/fphar.2014.00160
This article was submitted to Pharmacogenetics and Pharmacogenomics, a section of
the journal Frontiers in Pharmacology.
Copyright © 2014 Cree and Kennedy. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | Pharmacogenetics and Pharmacogenomics July 2014 | Volume 5 | Article 160 | 8
